Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Tesla Raises Cybertruck Prices by $5,000 in US 
Nvidia Options Price in $280 Billion Earnings Swing 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
SK Hynix Shares Fall as Workers Reject Wage Deal 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Add as a preferred source on Google
CHESTERBROOK, Pa., April 26, 2018 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will host a conference call and webcast on Thursday, May 3, 2018 at 8:00 am EDT to review financial results for the quarter ended March 31, 2018 and to discuss recent corporate highlights.
To join the call, please dial-in at (855) 465-0180 (conference ID: 1350009).
To join a live audio webcast of the call, please visit the Investor Presentation section of the Company’s website (conference ID: 1350009). Following the conclusion of the call, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on providing better, safer therapies to patients in pain. The Company has leveraged breakthrough science to discover and develop its investigational product, oliceridine injection, for the management of moderate-to-severe acute pain. Oliceridine has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration, and is intended to provide healthcare providers an innovative new option for patients who require an intravenous opioid. The Company also has an early stage pipeline of new chemical entities targeting novel mechanisms of action, including TRV250 for acute migraine, neuropathic pain, and other indications.
Contacts
Trevena, Inc.
Investors:
Jonathan Violin, Ph.D.
Senior Vice President, Scientific Affairs & Investor Relations Officer
610-354-8840 x231
[email protected]
or
Media:
Public Relations
[email protected]
